Skip to main content
All lobbying filings

APOTEX CORP.

Lobbying for APOTEX CORP.

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Expenses
$810,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Florida

Official filing document

 Government bodies contacted 3
  • HOUSE OF REPRESENTATIVES
  • Natl Economic Council (NEC)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • SJRES 37
    A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
 Lobbying activity 3
Manufacturing

Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives to spur domestic manufacturing of generic drugs.

Health Issues

Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings; and Federal policy relating to the structure of the Department of Health and Human Services.

Tariff (miscellaneous tariff bills)

America First Trade Policy Presidential Memorandum, provisions relating to a review of United States trade policies and agreements and the exemption of pharmaceuticals from tariffs; Executive Orders 14193, 14197, 14231, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Reciprocal Trade and Tariffs Presidential Memorandum, provisions relating to implementing reciprocal tariffs on countries that impose import duties on products from the United States and the exemption of pharmaceuticals from tariffs; and S.J.Res.37, provisions relating to terminating the national emergency declared on February 1, 2025, by the President in Executive Order 14193.

 Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • APOTEX INC.
    Canada · Toronto, Ontario · owns 0% of the client · contributed $0.00

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem